Cargando…

Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration

Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH). However, treatment with this medication remains problematic. Patients with 21-hydroxylase deficiency CAH have significant diurnal variation in the secretion of 17-hydroxyprogesterone (17OHP). When consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuqua, John S., Rotenstein, Deborah, Lee, Peter A.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850127/
https://www.ncbi.nlm.nih.gov/pubmed/20379352
http://dx.doi.org/10.1155/2010/712549
_version_ 1782179750977994752
author Fuqua, John S.
Rotenstein, Deborah
Lee, Peter A.
author_facet Fuqua, John S.
Rotenstein, Deborah
Lee, Peter A.
author_sort Fuqua, John S.
collection PubMed
description Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH). However, treatment with this medication remains problematic. Patients with 21-hydroxylase deficiency CAH have significant diurnal variation in the secretion of 17-hydroxyprogesterone (17OHP). When considering treatment strategies, this variation must be considered along with the pharmacokinetic and pharmacodynamic properties of exogenous glucocorticoids. Orally administered hydrocortisone is highly bioavailable, but it has a short time to maximum concentration (T(max)) and half life (T(1/2)). While prednisone has a somewhat longer T(max) and T(1/2), they remain relatively short. There have been several studies of the pharmacodynamics of hydrocortisone. We present data indicating that the maximum effect of hydrocortisone in CAH patients is seen 3 hours after a morning dose. After an evening dose, suppression of adrenal hormones continues until approximately 0500 the next day. In both situations, however, there is a large degree of intersubject variability. These data are consistent with earlier published studies. Use of alternate specimen types, possibly in conjunction with delayed release hydrocortisone preparations under development, may allow the practitioner to design a medication regimen that provides improved control of androgen secretion. Whatever dosing strategy is used, clinical judgment is required to ensure the best outcome.
format Text
id pubmed-2850127
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28501272010-04-08 Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration Fuqua, John S. Rotenstein, Deborah Lee, Peter A. Int J Pediatr Endocrinol Review Article Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH). However, treatment with this medication remains problematic. Patients with 21-hydroxylase deficiency CAH have significant diurnal variation in the secretion of 17-hydroxyprogesterone (17OHP). When considering treatment strategies, this variation must be considered along with the pharmacokinetic and pharmacodynamic properties of exogenous glucocorticoids. Orally administered hydrocortisone is highly bioavailable, but it has a short time to maximum concentration (T(max)) and half life (T(1/2)). While prednisone has a somewhat longer T(max) and T(1/2), they remain relatively short. There have been several studies of the pharmacodynamics of hydrocortisone. We present data indicating that the maximum effect of hydrocortisone in CAH patients is seen 3 hours after a morning dose. After an evening dose, suppression of adrenal hormones continues until approximately 0500 the next day. In both situations, however, there is a large degree of intersubject variability. These data are consistent with earlier published studies. Use of alternate specimen types, possibly in conjunction with delayed release hydrocortisone preparations under development, may allow the practitioner to design a medication regimen that provides improved control of androgen secretion. Whatever dosing strategy is used, clinical judgment is required to ensure the best outcome. Hindawi Publishing Corporation 2010 2010-03-31 /pmc/articles/PMC2850127/ /pubmed/20379352 http://dx.doi.org/10.1155/2010/712549 Text en Copyright © 2010 John S. Fuqua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Fuqua, John S.
Rotenstein, Deborah
Lee, Peter A.
Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title_full Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title_fullStr Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title_full_unstemmed Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title_short Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
title_sort duration of suppression of adrenal steroids after glucocorticoid administration
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850127/
https://www.ncbi.nlm.nih.gov/pubmed/20379352
http://dx.doi.org/10.1155/2010/712549
work_keys_str_mv AT fuquajohns durationofsuppressionofadrenalsteroidsafterglucocorticoidadministration
AT rotensteindeborah durationofsuppressionofadrenalsteroidsafterglucocorticoidadministration
AT leepetera durationofsuppressionofadrenalsteroidsafterglucocorticoidadministration